ArticleInfection and drug resistance2012
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.
Article in Infection and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07215273 (A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Infective Esophagitis.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Nursing management of pulmonary mucormycosis with skin damage secondary to amphotericin B colloidal dispersion: a case report.Frontiers in medicine · 2025Article
- Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology · 2023Review
- Antifungal lock therapy: an eternal promise or an effective alternative therapeutic approach?Letters in applied microbiology · 2022Review
- COVID-19-Associated Mucormycosis, A New Incident in Recent Time: Is An Emerging Disease in The Near Future Impending?Avicenna journal of medicine · 2021Review
- Mucormycosis.Infectious disease clinics of North America · 2021Review
- Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.Journal of nanobiotechnology · 2021Review
- Central Nervous System Infections Due to Aspergillus and Other Hyaline Molds.Journal of fungi (Basel, Switzerland) · 2019Review
- In vitro study of the variable effects of proton pump inhibitors on voriconazole.Antimicrobial agents and chemotherapy · 2015Article
- Invasive Fungal Sinusitis Involving the Orbital Apex in a Patient with Chronic Renal Failure.Neuro-ophthalmology (Aeolus Press) · 2015Article
- In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates.Journal of medical microbiology · 2014Article
- Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.International journal of clinical oncology · 2013Article
- Invasive fungal infections in transplant recipients.Therapeutic advances in infectious disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposomal amphotericin B is a "true" liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.